"The voice for cancer physicians and their patients in Massachusetts."

FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Pediatric Patients with Hodgkin Lymphoma

11 Nov 2022 3:03 PM | Katy Monaco (Administrator)

The Food and Drug Administration approved brentuximab vedotin (Adcetris, Seagen, Inc.) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients 2 years of age and older with previously untreated high risk classical Hodgkin lymphoma (cHL). This is the first pediatric approval for brentuximab vedotin. Read More.

Massachusetts Society of Clinical Oncologists ©2022

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  Fax: 781.464.4896  |  email: msco@mms.org

Powered by Wild Apricot Membership Software